Vol. 7, Issue 1, Part A (2025)

Diabetic nephropathy (DN) is one of the most serious complications of diabetes mellitus and a leading cause of end-stage renal disease (ESRD) globally. This paper provides a comprehensive examination of the pathophysiological mechanisms driving DN, the stages of disease progression, and the latest advancements in treatment strategies. Central to the development of DN are hyperglycemia-induced oxidative stress, chronic inflammation, and the activation of the renin-angiotensin-aldosterone system (RAAS), which collectively contribute to glomerular damage, proteinuria, and a decline in renal function. Current therapeutic approaches emphasize strict glycemic control, effective blood pressure management, and the use of novel agents that target specific molecular pathways involved in the disease process. 
Recent advancements in treatment include the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors, which have shown significant benefits in reducing albuminuria and slowing the decline in glomerular filtration rate (GFR), and mineralocorticoid receptor antagonists like finerenone, which address inflammation and fibrosis in the kidneys. Additionally, glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated renal protective effects beyond their glucose-lowering capabilities. 
This study underscores the critical importance of early diagnosis through regular screening for albuminuria and monitoring of GFR, particularly in high-risk patients. It also highlights the need for personalized, patient-specific interventions to optimize outcomes. Emerging therapies, including endothelin receptor antagonists and anti-inflammatory agents, offer promising avenues for further improving the management of DN. By integrating these advancements into clinical practice, healthcare providers can better slow disease progression, reduce the risk of ESRD, and enhance the quality of life for patients with diabetic nephropathy. 
In conclusion, this paper emphasizes the multifaceted nature of DN, from its underlying mechanisms to the latest therapeutic innovations, and calls for a proactive, individualized approach to diagnosis and treatment to address this growing global health challenge.